(2)
Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The activity will be performed in Recipharm s drug product manufacturing facility located in France.
Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it is anticipated that supply will commence in early 2021. We are making important progress in the development of the Moderna COVID-19 Vaccine and we are pleased to be entering into this collaboration with Recipharm, said Nicolas Chornet, Senior Vice President, International Manufacturing of Moderna. We look forward to their support in the delivery of our vaccine to market.
Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U S
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Recipharm : Sweden s Recipharm to help make Moderna s COVID-19 vaccine outside U S
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U S - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.